Introduction:: Coccinia indica, a medicinal plant known for its extensive pharmacological properties, has garnered increasing scientific interest due to its therapeutic potential. However, challenges such as poor bioavailability, low solubility, and rapid degradation of its bioactive compounds have limited its efficacy. Methods:: A literature search was performed to find studies regarding Coccinia indica (also known as Coccinia grandis) and its nanoformulations from 2015 to 2025, to bring together the latest developments in nanotechnology formulations of C. indica, such as nanoparticles, nanoemulsions, nanocarriers, and liposomes. Results:: Nano-based methods have shown improved solubility, stability, and targeted delivery of C. indica compounds. These strategies have enhanced controlled release, extended therapeutic effects, and boosted pharmacological effectiveness, while also minimizing possible side effects. Mechanistic insights reveal that nanotechnology helps in more efficient cellular absorption and improved pharmacokinetic characteristics. Discussion:: Even with these progressions, issues still remain in terms of scalability, evaluating long-term toxicity, gaining regulatory approval, and ensuring reproducibility of nanoformulations. To ensure their clinical relevance, it is crucial to tackle these issues through thorough preclinical studies and translational research. Conclusion:: By combining conventional medicine with contemporary nanotechnology, nanoformulations derived from Coccinia indica demonstrate significant promise in natural therapeutic practices and pharmaceutical innovation. Upcoming research concentrating on validating mechanisms, evaluating safety, and transitioning to clinical applications will clarify their potential as effective treatment alternatives.
Negi et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: